Jinxin Fertility Group Limited, a reproductive-health services provider listed on the Hong Kong Stock Exchange, filed a Next Day Disclosure Return on 10 June 2026 reporting further progress under its share repurchase programme.

On 10 June 2026 the company acquired 7.996 million ordinary shares on-market at prices ranging from HK$2.15 to HK$2.20, for a total consideration of HK$17.41 million. All of the repurchased shares are designated for cancellation.

Including this latest transaction, shares bought back but not yet cancelled aggregate 66.91 million, equivalent to roughly 2.47 % of the 2.71 billion shares in issue as of 9 June 2026. No new shares were issued during the period, leaving the company’s outstanding share capital unchanged at 2.71 billion shares pending cancellation of the repurchased stock.

Since the current shareholder mandate took effect on 26 June 2025, Jinxin Fertility has repurchased a cumulative 106.57 million shares, representing 3.88 % of the shares outstanding on the mandate date. With authorisation to buy back up to 274.47 million shares, the company still has capacity to repurchase an additional 167.90 million shares.

In line with Hong Kong listing regulations, a 30-day moratorium on new share issuance or treasury-share disposal is in force until 10 July 2026 following the latest repurchase. All transactions were carried out in compliance with Main Board Rule 10.06, and no shares are being held as treasury stock.